Introduction Alzheimer's disease (AD) is a major global public health challenge. To date, no
treatments have been shown to stop the underlying pathological processes. The cerebral …

Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying
treatments for Alzheimer disease to have received FDA-approval. There are three different …

Alzheimer's disease (AD) is common and devastating. However, current symptomatic
treatments are unable to alter the progression of the disease. Fortunately, many ongoing …

Purpose of review Discuss emerging anti-amyloid disease-modifying therapies for
Alzheimer's disease (AD) and outline how these therapies will change our clinical …

PURPOSE We conducted a meta-analysis to evaluate clinically meaningful benefits and
harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia …

Current status of amyloid-targeting immunotherapies for Alzheimer’s disease | Science
Translational Medicine news careers commentary Journals Science Science brought to you …

Abstract β-amyloid-targeting antibodies represent the first generation of effective causal
treatment of Alzheimer's disease (AD) and can be considered historical research milestones …

Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's
disease directed against amyloid‐β. This is a joint statement of the European Association of …

After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …